Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.

Ramsey JM, Kettyle LM, Sharpe DJ, Mulgrew NM, Dickson GJ, Bijl JJ, Austin P, Mayotte N, Cellot S, Lappin TR, Zhang SD, Mills KI, Krosl J, Sauvageau G, Thompson A.

Stem Cells. 2013 Jul;31(7):1434-45. doi: 10.1002/stem.1398.

2.

c-Met inhibition in a HOXA9/Meis1 model of CN-AML.

Mulgrew NM, Kettyle LM, Ramsey JM, Cull S, Smyth LJ, Mervyn DM, Bijl JJ, Thompson A.

Dev Dyn. 2014 Jan;243(1):172-81. doi: 10.1002/dvdy.24070.

3.

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C.

Blood. 2012 Sep 6;120(10):2118-26. doi: 10.1182/blood-2012-02-411827.

4.

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.

Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, Konopleva M, Andreeff M.

Leukemia. 2013 Jun;27(6):1358-68. doi: 10.1038/leu.2012.366.

5.

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

Dickson GJ, Liberante FG, Kettyle LM, O'Hagan KA, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A.

Haematologica. 2013 Aug;98(8):1216-25. doi: 10.3324/haematol.2012.079012.

6.

Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.

Schech A, Kazi A, Yu S, Shah P, Sabnis G.

Mol Cancer Ther. 2015 Aug;14(8):1848-57. doi: 10.1158/1535-7163.MCT-14-0778.

7.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496.

8.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

Blood. 2010 Nov 4;116(18):3622-6. doi: 10.1182/blood-2010-05-283648.

9.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742.

10.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R.

PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815.

11.

Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.

Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, Abdelkarim M, Hackanson B, Lübbert M.

PLoS One. 2013 Oct 8;8(10):e75258. doi: 10.1371/journal.pone.0075258.

12.

FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia.

Huang L, Zhou K, Yang Y, Shang Z, Wang J, Wang D, Wang N, Xu D, Zhou J.

Int J Hematol. 2012 Aug;96(2):234-40. doi: 10.1007/s12185-012-1115-9.

PMID:
22688855
14.

Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.

Kettyle LM, Liberante FG, Thompson A.

Methods Mol Biol. 2014;1196:349-70. doi: 10.1007/978-1-4939-1242-1_21.

PMID:
25151174
15.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr;124(4):1512-24. doi: 10.1172/JCI70921.

16.

A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.

Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, Yu L.

PLoS One. 2013;8(2):e55481. doi: 10.1371/journal.pone.0055481.

17.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA Jr, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A.

Nat Med. 2012 Mar 11;18(4):605-11. doi: 10.1038/nm.2661.

18.

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

Maiso P, Colado E, Ocio EM, Garayoa M, Martín J, Atadja P, Pandiella A, San-Miguel JF.

Leukemia. 2009 Dec;23(12):2265-74. doi: 10.1038/leu.2009.182.

PMID:
19812608
19.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730.

20.

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342.

PMID:
20038731
Items per page

Supplemental Content

Support Center